Angiogenesis as a target in neuroblastoma

Jochen Rössler; Melissa Taylor; Birgit Geoerger; Francoise Farace; Jeanette Lagodny; Regine Peschka-Süss; Charlotte M. Niemeyer; Gilles Vassal

doi:10.1016/j.ejca.2008.05.015

Angiogenesis as a target in neuroblastoma

Jochen Rössler, Melissa Taylor, Birgit Geoerger, Francoise Farace, Jeanette Lagodny, Regine Peschka-Süss, Charlotte M. Niemeyer, Gilles Vassal

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

56 Citations (Scopus)

Résumé

Several research investigations on neuroblastoma (NB) have shown the important dependency of this embryonic tumour on angiogenesis, especially in the advanced and aggressive stages. However, the first pre-clinical data on anti-angiogenic drugs in NB have not been published until recently and clinical trials with anti-angiogenic agents in NB treatment protocols are still missing. Here, we summarise current knowledge on the important role and mechanisms of angiogenesis in NB, and report available pre-clinical results of anti-angiogenic agents used to treat NB. This review clearly shows that angiogenesis is a target in NB and that clinical trials are urgently needed to bring forward promising anti-angiogenesis treatment strategies into NB therapy.

langue originale	Anglais
Pages (de - à)	1645-1656
Nombre de pages	12
journal	European Journal of Cancer
Volume	44
Numéro de publication	12
Les DOIs	https://doi.org/10.1016/j.ejca.2008.05.015
état	Publié - 1 août 2008

Accès au document

10.1016/j.ejca.2008.05.015

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{b84c61cf3420486fb33a39a96258f172,

title = "Angiogenesis as a target in neuroblastoma",

abstract = "Several research investigations on neuroblastoma (NB) have shown the important dependency of this embryonic tumour on angiogenesis, especially in the advanced and aggressive stages. However, the first pre-clinical data on anti-angiogenic drugs in NB have not been published until recently and clinical trials with anti-angiogenic agents in NB treatment protocols are still missing. Here, we summarise current knowledge on the important role and mechanisms of angiogenesis in NB, and report available pre-clinical results of anti-angiogenic agents used to treat NB. This review clearly shows that angiogenesis is a target in NB and that clinical trials are urgently needed to bring forward promising anti-angiogenesis treatment strategies into NB therapy.",

keywords = "Angiogenesis, Anti-angiogenesis, Bevacizumab, Neuroblastoma, VEGF",

author = "Jochen R{\"o}ssler and Melissa Taylor and Birgit Geoerger and Francoise Farace and Jeanette Lagodny and Regine Peschka-S{\"u}ss and Niemeyer, {Charlotte M.} and Gilles Vassal",

year = "2008",

month = aug,

day = "1",

doi = "10.1016/j.ejca.2008.05.015",

language = "English",

volume = "44",

pages = "1645--1656",

journal = "European Journal of Cancer",

issn = "0959-8049",

number = "12",

}

TY - JOUR

T1 - Angiogenesis as a target in neuroblastoma

AU - Rössler, Jochen

AU - Taylor, Melissa

AU - Geoerger, Birgit

AU - Farace, Francoise

AU - Lagodny, Jeanette

AU - Peschka-Süss, Regine

AU - Niemeyer, Charlotte M.

AU - Vassal, Gilles

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Several research investigations on neuroblastoma (NB) have shown the important dependency of this embryonic tumour on angiogenesis, especially in the advanced and aggressive stages. However, the first pre-clinical data on anti-angiogenic drugs in NB have not been published until recently and clinical trials with anti-angiogenic agents in NB treatment protocols are still missing. Here, we summarise current knowledge on the important role and mechanisms of angiogenesis in NB, and report available pre-clinical results of anti-angiogenic agents used to treat NB. This review clearly shows that angiogenesis is a target in NB and that clinical trials are urgently needed to bring forward promising anti-angiogenesis treatment strategies into NB therapy.

AB - Several research investigations on neuroblastoma (NB) have shown the important dependency of this embryonic tumour on angiogenesis, especially in the advanced and aggressive stages. However, the first pre-clinical data on anti-angiogenic drugs in NB have not been published until recently and clinical trials with anti-angiogenic agents in NB treatment protocols are still missing. Here, we summarise current knowledge on the important role and mechanisms of angiogenesis in NB, and report available pre-clinical results of anti-angiogenic agents used to treat NB. This review clearly shows that angiogenesis is a target in NB and that clinical trials are urgently needed to bring forward promising anti-angiogenesis treatment strategies into NB therapy.

KW - Angiogenesis

KW - Anti-angiogenesis

KW - Bevacizumab

KW - Neuroblastoma

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=48349134168&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2008.05.015

DO - 10.1016/j.ejca.2008.05.015

M3 - Article

C2 - 18614349

AN - SCOPUS:48349134168

SN - 0959-8049

VL - 44

SP - 1645

EP - 1656

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 12

ER -